{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:24:49Z","timestamp":1778642689631,"version":"3.51.4"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1097\/fpc.0000000000000341","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T05:08:31Z","timestamp":1527743311000},"page":"179-187","source":"Crossref","is-referenced-by-count":5,"title":["Brain neurotransmitter transporter\/receptor genomics and efavirenz central nervous system adverse events"],"prefix":"10.1097","volume":"28","author":[{"given":"David W.","family":"Haas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Bradford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anurag","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shefali S.","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph J.","family":"Eron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy M.","family":"Gulick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon A.","family":"Riddler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul E.","family":"Sax","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric S.","family":"Daar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gene D.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward P.","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marylyn D.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210213","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study","volume":"363","author":"van Leth","year":"2004","journal-title":"Lancet"},{"key":"R2-3-20210213","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1056\/NEJMoa031772","article-title":"Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection","volume":"350","author":"Gulick","year":"2004","journal-title":"N Engl J Med"},{"key":"R3-3-20210213","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"Riddler","year":"2008","journal-title":"N Engl J Med"},{"key":"R4-3-20210213","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"R5-3-20210213","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1086\/650697","article-title":"Maraviroc versus Efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection","volume":"201","author":"Cooper","year":"2010","journal-title":"J Infect Dis"},{"key":"R6-3-20210213","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-154-7-201104050-00316","article-title":"Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1","volume":"154","author":"Daar","year":"2011","journal-title":"Ann Intern Med"},{"key":"R7-3-20210213","doi-asserted-by":"crossref","first-page":"714","DOI":"10.7326\/0003-4819-143-10-200511150-00008","article-title":"Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals","volume":"143","author":"Clifford","year":"2005","journal-title":"Ann Intern Med"},{"key":"R8-3-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M14-0293","article-title":"Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data","volume":"161","author":"Mollan","year":"2014","journal-title":"Ann Intern Med"},{"key":"R10-3-20210213","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"R11-3-20210213","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbrc.2004.05.116","article-title":"Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens","volume":"319","author":"Tsuchiya","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"R12-3-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","article-title":"Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients","volume":"15","author":"Rotger","year":"2005","journal-title":"Pharmacogenet Genom"},{"key":"R13-3-20210213","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1086\/497610","article-title":"Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and\/or nelfinavir: an Adult AIDS Clinical Trials Group Study","volume":"192","author":"Haas","year":"2005","journal-title":"J Infect Dis"},{"key":"R14-3-20210213","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1086\/429327","article-title":"Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects","volume":"40","author":"Rodriguez-Novoa","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R15-3-20210213","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/FPC.0b013e32835a450b","article-title":"Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants","volume":"22","author":"Holzinger","year":"2012","journal-title":"Pharmacogenet Genom"},{"key":"R16-3-20210213","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn029","article-title":"Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients","volume":"61","author":"Wyen","year":"2008","journal-title":"J Antimicrob Chemo"},{"key":"R17-3-20210213","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.fpc.0000189797.03845.90","article-title":"Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz","volume":"16","author":"Wang","year":"2006","journal-title":"Pharmacogenet Genom"},{"key":"R18-3-20210213","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/655470","article-title":"Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study","volume":"202","author":"Ribaudo","year":"2010","journal-title":"J Infect Dis"},{"key":"R19-3-20210213","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/FPC.0b013e328328d577","article-title":"In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function","volume":"19","author":"di Iulio","year":"2009","journal-title":"Pharmacogenet Genom"},{"key":"R20-3-20210213","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2009.03368.x","article-title":"CYP2B6 (c.516G-->T) and CYP2A6 (*9B and\/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients","volume":"67","author":"Kwara","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"R21-3-20210213","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1097\/QAD.0b013e3283319908","article-title":"CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients","volume":"23","author":"Kwara","year":"2009","journal-title":"AIDS"},{"key":"R22-3-20210213","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1093\/jac\/dku110","article-title":"Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes","volume":"69","author":"Haas","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R23-3-20210213","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/FPC.0000000000000238","article-title":"Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race","volume":"26","author":"Leger","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"R24-3-20210213","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/infdis\/jix248","article-title":"Race\/Ethnicity and the pharmacogenetics of reported suicidality with efavirenz among clinical trials participants","volume":"216","author":"Mollan","year":"2017","journal-title":"J Infect Dis"},{"key":"R25-3-20210213","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/ng.3367","article-title":"A gene-based association method for mapping traits using reference transcriptome data","volume":"47","author":"Gamazon","year":"2015","journal-title":"Nat Genet"},{"key":"R26-3-20210213","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa030264","article-title":"Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection","volume":"349","author":"Robbins","year":"2003","journal-title":"N Engl J Med"},{"key":"R27-3-20210213","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa030265","article-title":"Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection","volume":"349","author":"Shafer","year":"2003","journal-title":"N Engl J Med"},{"key":"R28-3-20210213","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jama.296.7.769","article-title":"Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial","volume":"296","author":"Gulick","year":"2006","journal-title":"JAMA"},{"key":"R29-3-20210213","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1310\/MUQC-QXBC-8118-BPM5","article-title":"A multi-investigator\/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128","volume":"4","author":"Haas","year":"2003","journal-title":"HIV Clin Trials"},{"key":"R31-3-20210213","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1126\/science.1195271","article-title":"The major genetic determinants of HIV-1 control affect HLA class I peptide presentation","volume":"330","author":"Pereyra","year":"2010","journal-title":"Science"},{"key":"R32-3-20210213","doi-asserted-by":"crossref","first-page":"ofu113","DOI":"10.1093\/ofid\/ofu113","article-title":"Phenome-wide association study relating pretreatment laboratory parameters with human genetic variants in AIDS Clinical Trials Group Protocols","volume":"2","author":"Moore","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"R33-3-20210213","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","article-title":"PLINK: a tool set for whole-genome association and population-based linkage analyses","volume":"81","author":"Purcell","year":"2007","journal-title":"Am J Hum Genet"},{"key":"R35-3-20210213","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature09534","article-title":"A map of human genome variation from population-scale sequencing","volume":"467","author":"Genomes Project","year":"2010","journal-title":"Nature"},{"key":"R37-3-20210213","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nmeth.2307","article-title":"Improved whole-chromosome phasing for disease and population genetic studies","volume":"10","author":"Delaneau","year":"2013","journal-title":"Nat Methods"},{"key":"R38-3-20210213","doi-asserted-by":"crossref","first-page":"e1000529","DOI":"10.1371\/journal.pgen.1000529","article-title":"A flexible and accurate genotype imputation method for the next generation of genome-wide association studies","volume":"5","author":"Howie","year":"2009","journal-title":"PLoS Genet"},{"key":"R39-3-20210213","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3389\/fgene.2014.00370","article-title":"Imputation and quality control steps for combining multiple genome-wide datasets","volume":"5","author":"Verma","year":"2014","journal-title":"Front Genet"},{"key":"R41-3-20210213","first-page":"448","article-title":"Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression","volume":"23","author":"Li","year":"2018","journal-title":"Pac Symp Biocomput"},{"key":"R43-3-20210213","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40261-017-0605-1","article-title":"Discontinuation of efavirenz in paediatric patients: why do children switch?","volume":"38","author":"Wynberg","year":"2018","journal-title":"Clin Drug Investig"},{"key":"R44-3-20210213","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/cid\/cit747","article-title":"Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir\/lamivudine or tenofovir\/emtricitabine","volume":"58","author":"Smith","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R45-3-20210213","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2174\/1570162X113119990048","article-title":"Genetic variants of drug metabolizing enzymes and drug transporter (ABCB1) as possible biomarkers for adverse drug reactions in an HIV\/AIDS cohort in Zimbabwe","volume":"11","author":"Dhoro","year":"2013","journal-title":"Curr HIV Res"},{"key":"R46-3-20210213","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/jcph.533","article-title":"Markov model for characterizing neuropsychologic impairment and Monte Carlo simulation for optimizing efavirenz therapy","volume":"55","author":"Bisaso","year":"2015","journal-title":"J Clin Pharmacol"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:24:24Z","timestamp":1620951864000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201807000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000341","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}